ライフサイエンスコーパス: 5-HT(1A) agonist

1 s previously been reported for ipsapirone, a 5-HT1A agonist.

2 , but blunted by 10 microM buspirone, a weak 5-HT1A agonist.

3 by activating PV interneurons and by a TAAR1/5-HT(1A) agonist.

4 serotonergic agonist LSD and clinically used 5-HT(1A) agonists.

5 Subcutaneous injections of the selective 5-HT(1A) agonist 8-hydroxy-2-di-n-propylamino-tetralin (

6 se in the oxytocin and ACTH responses to the 5-HT(1A) agonist 8-hydroxy-dipropylamino-tetralin (8-OH-

7 injections were duplicated by injection of a 5-HT(1A) agonist 8-hydroxy-dipropylaminotetralin (8-OH-D

8 se it was blocked by coadministration of the 5-HT(1A) agonist 8-OH-DPAT [((+/-)-8-hydroxy-2-(di-n-pro

9 Administration of the 5-HT(1A) agonist 8-OH-DPAT resulted in decreases in frac

10 nd oxytocin responses to an injection of the 5-HT(1A) agonist 8-OH-DPAT.

11 ivity, with potency greater than that of the 5-HT(1A) agonist 8-OH-DPAT.

12 t serotonergic neurotransmission such as the 5-HT1A agonist 8-hydroxy-2-(di-n-propyl-amino)tetralin (

13 cal microdialysis perfusion of the selective 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetralin (

14 ctions of AVP in combination with either the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino) tetraline

15 [WAY100635] 0.5 mg/kg, intravenous) and the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin) [

16 Treatment with the 5-HT1A agonist 8-hydroxy-2-(di-n-propylmino)tetralin (8-

17 However, the 5-HT1A agonist 8-hydroxy-di-propylaminotetralin (8-OH-DP

18 onist NAN-190 (1 microM) and mimicked by the 5-HT1A agonist 8-OH-DPAT (1 microM).

19 Presession treatment with the 5-HT1A agonist 8-OH-DPAT (subcutaneous injections at a d

20 pharmacological approach, we found that the 5-HT1A agonist 8-OH-DPAT also potentiated the antidepres

21 Administration of low doses of the selective 5-HT1A agonists 8-OH-DPAT (5-20 micrograms/kg) and ipsap

22 ts (CP-93,129 and anpirtoline), but not by a 5-HT1A agonist (8-OH-DPAT), indicating that 5-HT1B recep

23 before and after unilaterally dialyzing the 5-HT1A agonist (+/-)-8-hydroxy-2-(dipropylamino)-tetrali

24 +/- 13 % of control (P < 0.001), as did the 5-HT1A agonist, 8-OH-DPAT (52.5 +/- 17 %, P < 0.001) and

25 complex (MS/DB) following injections of the 5-HT1A agonist, 8-OH-DPAT, into the median raphe nucleus

26 Next, a 5-HT1A agonist, 8-OH-DPAT, was coadministered with CP-15

27 rats (N = 10) received either saline or the 5-HT1A agonist, 8-OHDPAT (0.05 mg/kg) 20 min prior to a

28 ns DA release, rats were pretreated with the 5-HT1A agonist, 8-OHDPAT.

29 Microinjections of the selective 5-HT1A agonist, (+)-8-hydroxy-dipropylaminotetralin hydr

30 behavioral assays for hallucinogen-like and 5-HT(1A) agonist activity and in vitro radioligand compe

31 Both compounds also demonstrated partial 5-HT(1A) agonist activity in vivo in rat serotonin syndr

32 , 4-fluoro-5-methoxy-DMT (6), displayed high 5-HT(1A) agonist activity, with potency greater than tha

33 The combined treatment with FGF-2 and the 5-HT1A agonist also synergistically increased FGFR1 and

34 ood volume changes in the rat in response to 5-HT(1A) agonist and antagonist administration were meas

35 se autoreceptor preferring treatments with a 5-HT1A agonist and antagonist can strongly modify the be

36 in response to intravenous administration of 5-HT1A agonist and antagonist drugs.

37 with fibroblast growth factor 2 (FGF2) and a 5-HT1A agonist, and dependent on the heteroreceptor inte

38 nding autoradiography using [3H]8-OH-DPAT, a 5-HT1A agonist, and in situ hybridization using radiolab

39 5-HT(1A) agonists are neuroprotective in CNS injury mode

40 to be involved in the hypotensive actions of 5-HT(1A) agonists are unclear.

41 We also found that 5-HT(1A) agonists attenuate the proapoptotic effects of

42 ult indicates that this novel, high affinity 5-HT(1A) agonist, BAY X3702, is neuroprotective in this

43 effect of a novel, high affinity serotonin (5-HT1A) agonist, BAY X3702, in a rat model of acute subd

44 it is a promising tool for investigation of 5-HT(1A) agonist binding in the living human brain.

45 Systemic application of the somatodendritic 5-HT1A agonist BMY 7378 had a significantly greater supp

46 Simulations suggest that application of 5-HT(1A) agonists can mitigate the respiratory pathology

47 se results imply a potential clinical use of 5-HT1A agonists for post-SCI respiratory disorders.

48 -hydroxy-dipropylaminotetralin (8-OHDPAT), a 5-HT1A agonist, has anxiolytic properties.

49 udies, we present an argument for the use of 5-HT(1A) agonists in the treatment of Dup15q epilepsy.

50 -2-di-(n-propylamino) tetralin hydrobromide; 5-HT(1A) agonist; in vivo] reduced respiratory instabili

51 mic administration of either full or partial 5-HT1A agonists increases neuroendocrine responses and t

52 In vitro and in vivo studies also revealed a 5-HT1A agonist induced phosphorylation of FGFR1 and extr

53 induced prolactin response, but also blunted 5-HT(1A) agonist-induced hypothermia and increased 5-HT(

54 adigm using rats trained to discriminate the 5-HT(1A) agonist LY293284 was 0.17 micromol/kg, and the

55 However, 3a and 3b fully substituted for the 5-HT1A agonist LY293284 ((-)-(4R)-6-acetyl-4-(di-n-propy

56 as suggested experimentally, that effects of 5-HT(1A) agonists on the respiratory neural circuit suff

57 effect of a serotonin (5-hydroxytryptamine, 5-HT(1A)) agonist on these processes was investigated.

58 s of 50mM ethanol and 100nM of ipsapirone, a 5-HT(1A) agonist, on the expression of several NF-kappaB

59 , a potential high affinity (K(i) = 1.36 nM) 5-HT(1A) agonist PET tracer is described.

60 5-HT(1A) agonists provided potent and complete functiona

61 he [35S]GTPgammaS labeling stimulated by the 5-HT1A agonist (R)-8-hydroxy-2-dipropylaminotetralin [(R

62 ed when the 5-hydroxytryptamine 1A receptor (5-HT1A) agonist (R)-(+)-8-hydroxy-2(di-n-propylamino)tet

63 ne-3,5(2H,4H)dione ((11)C-CUMI-101), a novel 5-HT(1A) agonist radiotracer, in Papio anubis.

64 78 alone and in combination with these other 5-HT1A agonists reduced copulatory behavior, though not

65 sion of Rh-CT(5-HT1A), but not Rh, decreases 5-HT(1A) agonist sensitivity, suggesting that Rh-CT(5-HT

66 Hypothalamic injection of a 5-HT1a agonist stimulated aggression in female hamsters

67 which is released from astrocytes following 5-HT(1A) agonist stimulation, can reduce apoptosis in et

68 Thus, effects on breathing of 5-HT(1a) agonists, such as (R)-(+)-8-hydroxy-2-(di-N-pro

69 tration of either azapirone or aminotetralin 5-HT1A agonists, such as 8-hydroxy-2-dipropylaminotetral

70 SSRIs share with anxiolytic 5-HT(1A) agonists the ability to produce desensitization

71 fects are mediated in part by the ability of 5-HT(1A) agonists to activate the phosphatidyl 3'-kinase

72 Application of serotonin or 5-HT(1A) agonists to PFC slices reduced CaMKII activity

73 The authors evaluated the efficacy of 5-HT(1A) agonists to protect the retina from severe blue

74 r disruption compromises the ability of this 5-HT1A agonist to antagonize the feeding suppressant act

75 Using a 5-HT(1A) agonist we were able to attenuate the ethanol-a

76 Piperazine 10 is a 5-HT(1A) agonist with an EC(50) comparable to serotonin,